{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:53:21Z","timestamp":1790909601039,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA098252"],"award-info":[{"award-number":["P50CA098252"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21DE034547"],"award-info":[{"award-number":["R21DE034547"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Calreticulin (CRT) is an endoplasmic reticulum chaperone that facilitates antigen processing and presentation, making it an attractive fusion partner for enhancing tumor-specific T-cell responses in DNA vaccine development. However, the relative efficacy of CRT compared with other antigen-presentation\u2013enhancing strategies has not been fully evaluated. We constructed a DNA vaccine encoding the immunodominant human papillomavirus (HPV)-16 E7 minigene epitope (aa 49\u201357) fused to the C-terminus of CRT (pcDNA3-CRT-E7(49\u201357), hereafter CRT-E7(49\u201357)). This vaccine was compared with DNA vaccines encoding CRT linked to full-length E7 (CRT-E7(1\u201398)) and other antigen-presentation\u2013enhancing constructs, including ubiquitin linked to E7 minigene (Ub-E7(49\u201357)) and MHC class I trafficking domain linked to E7 minigene (MITD-E7 (49\u201357)). We evaluated E7-specific cytotoxic T-cell responses, tumor volume, and survival in both prophylactic and therapeutic TC-1 tumor models. Intramuscular electroporation of C57BL\/6 mice with CRT-E7(49\u201357) elicited robust E7-specific CD8\u207a T-cell responses comparable to those induced by CRT-E7(1\u201398) and MITD-E7(49\u201357), but higher than those elicited by Ub-E7 (49\u201357). CRT-E7(49\u201357) vaccination provided complete protection against TC-1 tumor challenge, with mice remaining tumor-free and surviving beyond 60 days. Vaccinated mice also exhibited strong immune memory, as tumor rechallenge triggered potent E7-specific CD8\u207a T-cell responses and restricted tumor growth. In therapeutic settings, two doses of CRT-E7(49\u201357) completely suppressed tumor progression, outperforming Ub-E7(49\u201357) and conferring superior survival compared with MITD-E7(49\u201357). The CRT-E7(49\u201357) DNA vaccine induces durable, high-magnitude E7-specific CD8\u207a T-cell responses and confers effective prophylactic and therapeutic antitumor immunity, underscoring its promise as a versatile platform for cancer immunotherapy.<\/jats:p>","DOI":"10.1038\/s41598-026-58415-z","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:46:15Z","timestamp":1783100775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A calreticulin-linked HPV-16 E7 minigene DNA vaccine elicits strong E7-specific CD8+ T-cell immunity and durable antitumor effects in a preclinical model"],"prefix":"10.1038","volume":"16","author":[{"given":"Yu-Cheng","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chea","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Long","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Fu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"1","key":"58415_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.it.2012.08.002","volume":"34","author":"M Raghavan","year":"2013","unstructured":"Raghavan, M., Wijeyesakere, S. J., Peters, L. R. & Del Cid, N. Calreticulin in the immune system: ins and outs. Trends Immunol. 34 (1), 13\u201321 (2013).","journal-title":"Trends Immunol."},{"issue":"1","key":"58415_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF00925962","volume":"135","author":"PD Nash","year":"1994","unstructured":"Nash, P. D., Opas, M. & Michalak, M. Calreticulin: not just another calcium-binding protein. Mol. Cell. Biochem. 135 (1), 71\u201378 (1994).","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"58415_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","volume":"31","author":"J Fucikova","year":"2021","unstructured":"Fucikova, J., Spisek, R., Kroemer, G. & Galluzzi, L. Calreticulin and cancer. Cell. Res. 31 (1), 5\u201316 (2021).","journal-title":"Cell. Res."},{"key":"58415_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","volume":"31","author":"JS Blum","year":"2013","unstructured":"Blum, J. S., Wearsch, P. A. & Cresswell, P. Pathways of antigen processing. Annu. Rev. Immunol. 31, 443\u2013473 (2013).","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"58415_CR5","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1038\/s41467-022-32384-z","volume":"13","author":"A Domnick","year":"2022","unstructured":"Domnick, A. et al. Molecular basis of MHC I quality control in the peptide loading complex. Nat. Commun. 13 (1), 4701 (2022).","journal-title":"Nat. Commun."},{"key":"58415_CR6","doi-asserted-by":"crossref","unstructured":"Spee, P. & Neefjes, J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur. J. Immunol. 27 (9), 2441\u20132449 (1997 Sept).","DOI":"10.1002\/eji.1830270944"},{"issue":"1","key":"58415_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1074-7613(01)00260-6","volume":"16","author":"B Gao","year":"2002","unstructured":"Gao, B. et al. Assembly and Antigen-Presenting Function of MHC Class I Molecules in Cells Lacking the ER Chaperone Calreticulin. Immunity 16 (1), 99\u2013109 (2002).","journal-title":"Immunity"},{"key":"58415_CR8","doi-asserted-by":"crossref","unstructured":"Zaidi, N., Jaffee, E. M. & Yarchoan, M. Recent advances in therapeutic cancer vaccines. Nat. Rev. Cancer. 25 (7), 517\u2013533 (2025 July).","DOI":"10.1038\/s41568-025-00820-z"},{"issue":"3","key":"58415_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18 (3), 168\u2013182 (2018).","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"58415_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24 (3), 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"58415_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18 (4), 215\u2013229 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"58415_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F., Schr\u00f6rs, B., L\u00f6wer, M., T\u00fcreci, \u00d6. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21 (4), 261\u2013282 (2022).","journal-title":"Nat. Rev. Drug Discov"},{"key":"58415_CR13","doi-asserted-by":"publisher","first-page":"1332939","DOI":"10.3389\/fimmu.2024.1332939","volume":"15","author":"B Lu","year":"2024","unstructured":"Lu, B. et al. The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects. Front. Immunol. 15, 1332939 (2024).","journal-title":"Front. Immunol."},{"key":"58415_CR14","doi-asserted-by":"crossref","unstructured":"Neeli, P., Chai, D., Roy, D., Prajapati, S. & Bonam, S. R. DNA Vaccines in the Post-mRNA Era: Engineering, Applications, and Emerging Innovations. Int. J. Mol. Sci. 2025 Sept 7;26(17):8716 .","DOI":"10.3390\/ijms26178716"},{"issue":"1","key":"58415_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12929-024-01102-w","volume":"32","author":"HC Liao","year":"2025","unstructured":"Liao, H. C. & Liu, S. J. Advances in nucleic acid-based cancer vaccines. J. Biomed. Sci. 32 (1), 10 (2025).","journal-title":"J. Biomed. Sci."},{"issue":"3","key":"58415_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-22-1987","volume":"29","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal, C. et al. Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. Off J. Am. Assoc. Cancer Res. 29 (3), 560\u2013570 (2023).","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res."},{"issue":"10008","key":"58415_CR17","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Lond. Engl. 386 (10008), 2078\u20132088 (2015).","journal-title":"Lancet Lond. Engl."},{"issue":"12","key":"58415_CR18","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","volume":"21","author":"JW Youn","year":"2020","unstructured":"Youn, J. W. et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 21 (12), 1653\u20131660 (2020).","journal-title":"Lancet Oncol."},{"key":"58415_CR19","doi-asserted-by":"crossref","unstructured":"Cheng, W. F. et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108 (5), 669\u2013678 (2001 Sept).","DOI":"10.1172\/JCI200112346"},{"issue":"4","key":"58415_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/biom4040994","volume":"4","author":"N Vigneron","year":"2014","unstructured":"Vigneron, N. & Van den Eynde, B. J. Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules 4 (4), 994\u20131025 (2014).","journal-title":"Biomolecules"},{"issue":"8","key":"58415_CR21","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.vaccine.2009.10.096","volume":"28","author":"L Li","year":"2010","unstructured":"Li, L. et al. Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. Vaccine 28 (8), 1911\u20131918 (2010).","journal-title":"Vaccine"},{"issue":"1","key":"58415_CR22","doi-asserted-by":"publisher","first-page":"e27529","DOI":"10.4161\/onci.27529","volume":"3","author":"L Aurisicchio","year":"2014","unstructured":"Aurisicchio, L. et al. A novel minigene scaffold for therapeutic cancer vaccines. Oncoimmunology 3 (1), e27529 (2014).","journal-title":"Oncoimmunology"},{"issue":"3","key":"58415_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/vaccines13030248","volume":"13","author":"J Li","year":"2025","unstructured":"Li, J., Ju, Y., Jiang, M., Li, S. & Yang, X. Y. Epitope-Based Vaccines: The Next Generation of Promising Vaccines Against Bacterial Infection. Vaccines 13 (3), 248 (2025).","journal-title":"Vaccines"},{"issue":"1","key":"58415_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13073-021-00872-4","volume":"13","author":"L Li","year":"2021","unstructured":"Li, L. et al. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. Genome Med. 13 (1), 56 (2021).","journal-title":"Genome Med."},{"issue":"4","key":"58415_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/vaccines12040392","volume":"12","author":"N Guo","year":"2024","unstructured":"Guo, N. et al. Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins. Vaccines 12 (4), 392 (2024).","journal-title":"Vaccines"},{"key":"58415_CR26","doi-asserted-by":"crossref","unstructured":"Peng, K., Zhao, X., Fu, Y. X. & Liang, Y. Eliciting antitumor immunity via therapeutic cancer vaccines. Cell. Mol. Immunol. 2025 July 9;22(8):840\u2013868 .","DOI":"10.1038\/s41423-025-01316-4"},{"issue":"19","key":"58415_CR27","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl. J. Med. 361 (19), 1838\u20131847 (2009).","journal-title":"N Engl. J. Med."},{"issue":"10","key":"58415_CR28","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/eji.201343324","volume":"43","author":"RA Rosalia","year":"2013","unstructured":"Rosalia, R. A. et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur. J. Immunol. 43 (10), 2554\u20132565 (2013).","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"58415_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli, E. et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 5 (1), 67\u201373 (2019).","journal-title":"JAMA Oncol."},{"issue":"686","key":"58415_CR30","doi-asserted-by":"publisher","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"J Ramos da Silva","year":"2023","unstructured":"Ramos da Silva, J. et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci. Transl Med. 15 (686), eabn3464 (2023).","journal-title":"Sci. Transl Med."},{"issue":"12","key":"58415_CR31","first-page":"4707","volume":"2017","author":"T Kanuma","year":"1950","unstructured":"Kanuma, T. et al. CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8\u2009+\u2009T Cell Responses. J. Immunol. Baltim. Md. 2017 (12), 4707\u20134715 (1950).","journal-title":"J. Immunol. Baltim. Md."},{"issue":"3","key":"58415_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/vaccines12030280","volume":"12","author":"D El Safadi","year":"2024","unstructured":"El Safadi, D. et al. Exosome-Mediated Antigen Delivery: Unveiling Novel Strategies in Viral Infection Control and Vaccine Design. Vaccines 12 (3), 280 (2024).","journal-title":"Vaccines"},{"key":"58415_CR33","doi-asserted-by":"crossref","unstructured":"He, J. et al. Tuning the fluidity and protein corona of ultrasound-responsive liposomal nanovaccines to program T cell immunity in mice. Nat. Commun. 2024 Sept 16;15(1):8121 .","DOI":"10.1038\/s41467-024-52104-z"},{"issue":"2","key":"58415_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11373-005-0334-y","volume":"12","author":"CT Lin","year":"2005","unstructured":"Lin, C. T. et al. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin. J. Biomed. Sci. 12 (2), 279\u2013287 (2005).","journal-title":"J. Biomed. Sci."},{"issue":"7\u20138","key":"58415_CR35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41434-023-00388-z","volume":"30","author":"S Tominaga","year":"2023","unstructured":"Tominaga, S. et al. Induced pluripotent stem cell-derived dendritic cell vaccine therapy genetically modified on the ubiquitin-proteasome system. Gene Ther. 30 (7\u20138), 552\u2013559 (2023).","journal-title":"Gene Ther."},{"issue":"1-2","key":"58415_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0304-3835(03)00102-2","volume":"197","author":"N Huebener","year":"2003","unstructured":"Huebener, N. et al. Vaccination with minigenes encoding for novel self antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett. 197 (1-2), 211\u2013217 (2003). July 18.","journal-title":"Cancer Lett."},{"key":"#cr-split#-58415_CR37.1","unstructured":"Luozhong, S. et al. Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity. Nat Mater [Internet]. May 29 [cited 2025 Oct 1]"},{"key":"#cr-split#-58415_CR37.2","unstructured":"(2025). Available from: https:\/\/www.nature.com\/articles\/s41563-025-02240-8"},{"issue":"1","key":"58415_CR38","first-page":"309","volume":"180","author":"S Kreiter","year":"2008","unstructured":"Kreiter, S. et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J. Immunol. Baltim. Md. 1950. 180 (1), 309\u2013318 (2008).","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"58415_CR39","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nat. 2017 July 13;547(7662):222\u2013226 ."},{"key":"58415_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-biochem-051810-094654","volume":"81","author":"K Husnjak","year":"2012","unstructured":"Husnjak, K. & Dikic, I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu. Rev. Biochem. 81, 291\u2013322 (2012).","journal-title":"Annu. Rev. Biochem."},{"issue":"16","key":"58415_CR41","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","volume":"105","author":"P Leone","year":"2013","unstructured":"Leone, P. et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J. Natl. Cancer Inst. 105 (16), 1172\u20131187 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"58415_CR42","doi-asserted-by":"crossref","unstructured":"Andersson, H. A. & Barry, M. A. Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol. Ther. J. Am. Soc. Gene Ther. 10 (3), 432\u2013446 (2004 Sept).","DOI":"10.1016\/j.ymthe.2004.05.035"},{"issue":"11","key":"58415_CR43","doi-asserted-by":"publisher","first-page":"8497","DOI":"10.1128\/jvi.71.11.8497-8503.1997","volume":"71","author":"F Rodriguez","year":"1997","unstructured":"Rodriguez, F., Zhang, J. & Whitton, J. L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71 (11), 8497\u20138503 (1997).","journal-title":"J. Virol."},{"issue":"8","key":"58415_CR44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/104454999315024","volume":"18","author":"O Vidalin","year":"1999","unstructured":"Vidalin, O., Tanaka, E., Spengler, U., Tr\u00e9po, C. & Inchausp\u00e9, G. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell. Biol. 18 (8), 611\u2013621 (1999).","journal-title":"DNA Cell. Biol."},{"key":"58415_CR45","doi-asserted-by":"crossref","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nat. 2016 June 16;534(7607):396\u2013401 .","DOI":"10.1038\/nature18300"},{"key":"58415_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13578-017-0171-5","volume":"7","author":"A Yang","year":"2017","unstructured":"Yang, A. et al. Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus. Cell. Biosci. 7, 46 (2017).","journal-title":"Cell. Biosci."},{"issue":"5","key":"58415_CR47","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/75406","volume":"18","author":"NP Dantuma","year":"2000","unstructured":"Dantuma, N. P., Lindsten, K., Glas, R., Jellne, M. & Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin\/proteasome-dependent proteolysis in living cells. Nat. Biotechnol. 18 (5), 538\u2013543 (2000).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"58415_CR48","first-page":"21","volume":"56","author":"KY Lin","year":"1996","unstructured":"Lin, K. Y. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56 (1), 21\u201326 (1996).","journal-title":"Cancer Res."},{"key":"58415_CR49","doi-asserted-by":"crossref","unstructured":"Shen, Z., Reznikoff, G., Dranoff, G. & Rock, K. L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol Baltim Md. 1997;158(6):2723\u201330. (1950).","DOI":"10.4049\/jimmunol.158.6.2723"},{"issue":"9","key":"58415_CR50","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.gt.3301160","volume":"7","author":"TL Wang","year":"2000","unstructured":"Wang, T. L. et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. 7 (9), 726\u2013733 (2000).","journal-title":"Gene Ther."},{"issue":"3","key":"58415_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00262-016-1793-x","volume":"65","author":"S Peng","year":"2016","unstructured":"Peng, S. et al. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes. Cancer Immunol. Immunother CII. 65 (3), 261\u2013271 (2016).","journal-title":"Cancer Immunol. Immunother CII"},{"key":"58415_CR52","doi-asserted-by":"crossref","unstructured":"Michalek, M. T., Grant, E. P., Gramm, C., Goldberg, A. L. & Rock, K. L. A role for the ubiquitin-dependent proteolytic pathway in MHC class l-restricted antigen presentation. Nat. 1993 June 10;363(6429):552\u2013554 .","DOI":"10.1038\/363552a0"},{"issue":"15","key":"58415_CR53","doi-asserted-by":"publisher","first-page":"7616","DOI":"10.1128\/JVI.76.15.7616-7624.2002","volume":"76","author":"SA Leachman","year":"2002","unstructured":"Leachman, S. A. et al. Ubiquitin-Fused and\/or Multiple Early Genes from Cottontail Rabbit Papillomavirus as DNA Vaccines. J. Virol. 76 (15), 7616\u20137624 (2002).","journal-title":"J. Virol."},{"issue":"5","key":"58415_CR54","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1084\/jem.185.5.909","volume":"185","author":"TW Tobery","year":"1997","unstructured":"Tobery, T. W. & Siliciano, R. F. Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization. J. Exp. Med. 185 (5), 909\u2013920 (1997).","journal-title":"J. Exp. Med."},{"issue":"18","key":"58415_CR55","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0264-410X(98)00134-0","volume":"16","author":"T Fu","year":"1998","unstructured":"Fu, T. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vaccine 16 (18), 1711\u20131717 (1998).","journal-title":"Vaccine"},{"issue":"4","key":"58415_CR56","first-page":"1904","volume":"186","author":"L Huang","year":"2011","unstructured":"Huang, L., Marvin, J. M., Tatsis, N. & Eisenlohr, L. C. Cutting Edge: Selective role of ubiquitin in MHC class I antigen presentation. J. Immunol. Baltim. Md. 1950. 186 (4), 1904\u20131908 (2011).","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"58415_CR57","doi-asserted-by":"crossref","unstructured":"Goth, S., Nguyen, V. & Shastri, N. Generation of naturally processed peptide\/MHC class I complexes is independent of the stability of endogenously synthesized precursors. J Immunol Baltim Md. 1996 Sept 1;157(5):1894\u2013904. (1950).","DOI":"10.4049\/jimmunol.157.5.1894"},{"key":"58415_CR58","unstructured":"Bolhassani, A. & Yazdi, S. R. DNA immunization as an efficient strategy for vaccination. Avicenna J. Med. Biotechnol. 1 (2), 71\u201388 (2009 July)."},{"key":"58415_CR59","doi-asserted-by":"crossref","unstructured":"Shirota, H., Petrenko, L., Hong, C. & Klinman, D. M. Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. J Immunol Baltim Md. 2007 July 1;179(1):329\u201336. (1950).","DOI":"10.4049\/jimmunol.179.1.329"},{"key":"58415_CR60","doi-asserted-by":"publisher","first-page":"e10709","DOI":"10.1002\/btm2.10709","volume":"10","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. MHCI trafficking signal-based mRNA vaccines strengthening immune protection against RNA viruses. Bioeng. Transla Med. 10, e10709 (2025).","journal-title":"Bioeng. Transla Med."},{"key":"58415_CR61","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/ijms27042039","volume":"27","author":"S Cao","year":"2026","unstructured":"Cao, S. et al. A DNA Vaccine Incorporating the MHC Class I Trafficking Domain and PADRE Epitope Enhances Antitumor Immunity in a Murine Pancreatic Cancer Model. IJMS 27, 2039 (2026).","journal-title":"IJMS"},{"key":"58415_CR62","doi-asserted-by":"publisher","first-page":"587237","DOI":"10.3389\/fonc.2020.587237","volume":"10","author":"X Ye","year":"2020","unstructured":"Ye, X., Li, W., Huang, J., Zhang, L. & Zhang, Y. Cytotoxic T Cell Responses Induced by CS1\/CRT Fusion DNA Vaccine in a Human Plasmacytoma Model. Front. Oncol. 10, 587237 (2020).","journal-title":"Front. Oncol."},{"key":"58415_CR63","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1242\/jcs.02856","volume":"119","author":"DB Williams","year":"2006","unstructured":"Williams, D. B. Beyond lectins: the calnexin\/calreticulin chaperone system of the endoplasmic reticulum. J. Cell Sci. 119, 615\u2013623 (2006).","journal-title":"J. Cell Sci."},{"key":"58415_CR64","doi-asserted-by":"crossref","unstructured":"Zhou, Z. P. et al. DNA-Based Vaccines: Advances, Applications, and Future Prospects. Genes & Diseases. ;102025. (2026).","DOI":"10.1016\/j.gendis.2025.102025"},{"key":"58415_CR65","doi-asserted-by":"publisher","first-page":"1584876","DOI":"10.3389\/fimmu.2025.1584876","volume":"16","author":"EN Konopka","year":"2025","unstructured":"Konopka, E. N., Edgerton, A. O. & Kutzler, M. A. Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations. Front. Immunol. 16, 1584876 (2025).","journal-title":"Front. Immunol."},{"issue":"5","key":"58415_CR66","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1128\/IAI.01722-07","volume":"76","author":"YS Park","year":"2008","unstructured":"Park, Y. S., Lee, J. H., Hung, C. F., Wu, T. C. & Kim, T. W. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect. Immun. 76 (5), 1952\u20131959 (2008).","journal-title":"Infect. Immun."},{"issue":"9","key":"58415_CR67","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1128\/JVI.78.9.4638-4645.2004","volume":"78","author":"TW Kim","year":"2004","unstructured":"Kim, T. W. et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol. 78 (9), 4638\u20134645 (2004).","journal-title":"J. Virol."},{"issue":"1","key":"58415_CR68","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamaoncol.2022.5143","volume":"9","author":"MLN Disis","year":"2023","unstructured":"Disis, M. L. N. et al. Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 9 (1), 71\u201378 (2023).","journal-title":"JAMA Oncol."},{"issue":"16","key":"58415_CR69","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS Rosa","year":"2021","unstructured":"Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. & Marques, M. P. C. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine 39 (16), 2190\u20132200 (2021).","journal-title":"Vaccine"},{"key":"58415_CR70","doi-asserted-by":"crossref","unstructured":"Bell, H. N. & Zou, W. Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance. Annu. Rev. Immunol. 42 (1), 521\u2013550 (2024 June).","DOI":"10.1146\/annurev-immunol-101819-024752"},{"issue":"1","key":"58415_CR71","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu, M. et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol. Cancer. 23 (1), 92 (2024).","journal-title":"Mol. Cancer"},{"issue":"2","key":"58415_CR72","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis, K. M. et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann. Oncol. Off J. Eur. Soc. Med. Oncol. 30 (2), 219\u2013235 (2019).","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"issue":"10278","key":"58415_CR73","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","volume":"397","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam, F., Larkin, J., Tabernero, J. & Bonini, C. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet Lond. Engl. 397 (10278), 1010\u20131022 (2021).","journal-title":"Lancet Lond. Engl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58415-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58415-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58415-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:02:23Z","timestamp":1790906543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58415-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58415"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58415-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.C.W. is a co-founder of and has an equity ownership interest in Papivax LLC. Also, he owns Papivax Biotech Inc. stock options and is a member of Papivax Biotech Inc.\u2019s Scientific Advisory Board. Additionally, under a licensing agreement between Papivax Biotech Inc. and the Johns Hopkins University, T.C.W. and CF.H. are entitled to royalties on an invention described in this article. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflicts of interest policies. Other co-authors declared no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Ethical statement<\/b>"}},{"value":"for this study was obtained from Animal Care and Use Committee at Johns Hopkins University (Protocol Number: MO23M84).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"<b>Ethical statement<\/b>"}}],"article-number":"30645"}}